After Pfizer's vaccine data, analysts say COVID19 drugmakers face questions about long-term sales prospects

While stocks are up big Monday, the analysts said they expect share price pressure on drugmakers with leading therapeutics. Investors have higher revenue expectations for Gilead’s Veklury than they do for antibodies from Eli Lilly and Regeneron, the analysts wrote, so they expected “the most pressure” on the California drugmaker among that group.